Xenon Pharmaceuticals Inc. (XENE)

Market Cap	2.74B
Revenue (ttm)	n/a
Net Income (ttm)	-234.33M
Shares Out	76.54M
EPS (ttm)	-3.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,183,389
Open	35.70
Previous Close	35.02
Day's Range	35.56 - 36.96
52-Week Range	26.74 - 46.00
Beta	1.22
Analysts	Strong Buy
Price Target	56.22 (+56.82%)
Earnings Date	May 12, 2025

About XENE

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2014
• Employees: 327
• Stock Exchange: NASDAQ
• Ticker Symbol: XENE
• Website: https://www.xenon-pharma.com

Analyst Forecast

According to 9 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price forecast is $56.22, which is an increase of 56.82% from the latest price.

Price Target

$56.22

(56.82% upside)

Analyst Consensus: Strong Buy